Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) shot up 2.3% during trading on Tuesday . The company traded as high as $9.50 and last traded at $9.41. 2,611 shares changed hands during mid-day trading, a decline of 27% from the average session volume of 3,555 shares. The stock had previously closed at $9.20.
Telix Pharmaceuticals Stock Performance
The stock’s 50 day moving average is $9.93 and its two-hundred day moving average is $8.60.
About Telix Pharmaceuticals
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
Recommended Stories
- Five stocks we like better than Telix Pharmaceuticals
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
